Chemoradiation With SABR Boost Safe, Effective for Advanced Lung Cancer

Follow Drugslib on

Medically reviewed by Drugs.com.

By Elana Gotkine HealthDay Reporter

TUESDAY, Jan. 16, 2024 -- Chemoradiation with an adaptive stereotactic ablative radiotherapy (SABR) boost is safe and effective for patients with locally advanced, unresectable non–small cell lung cancer (NSCLC), according to a study published online Jan. 11 in JAMA Oncology.

Trudy C. Wu, M.D., from the University of California in Los Angeles, and colleagues examined the maximum tolerated dose (MTD) and use of hypofractionated concurrent chemoradiation with an adaptive SABR boost among patients with clinical stage II or III NSCLC. All patients first received 4 Gy x 10 fractions followed by an adaptive SABR boost consisting of an additional 25 Gy (low), 30 Gy (intermediate), or 35 Gy (high) with concurrent weekly carboplatin/paclitaxel. Data were evaluated from 28 patients (24 with stage III disease) enrolled across the low-, intermediate-, and high-dose cohorts (10, nine, and nine, respectively).

The researchers found that the protocol-specified MTD was not exceeded in the study. Nonhematologic acute and late grade 3 or higher effects had incidences of 11 and 7 percent, respectively. In the intermediate-dose boost cohort, there were no grade 3 toxic effects. In the high-dose cohort, there were two deaths. For the low-, intermediate-, and high-dose cohorts, two-year local control was 74.1, 85.7, and 100.0 percent, respectively, and two-year overall survival was 30.0, 76.2, and 55.6 percent, respectively.

"The present findings suggest that increasing the BED [biologic effective dose] through hypofractionation may enhance LC [local control], but this approach is limited by grade 5 toxic effects beyond a certain BED, which was 70 Gy in 15 fractions in this study," the authors write.

Several authors disclosed ties to the pharmaceutical industry.

Abstract/Full Text (subscription or payment may be required)

Editorial (subscription or payment may be required)

Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.

Source: HealthDay

Posted : 2024-01-17 00:15

Read more

Disclaimer

Every effort has been made to ensure that the information provided by Drugslib.com is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Drugslib.com information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Drugslib.com does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Drugslib.com's drug information does not endorse drugs, diagnose patients or recommend therapy. Drugslib.com's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.

The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Drugslib.com does not assume any responsibility for any aspect of healthcare administered with the aid of information Drugslib.com provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.

Popular Keywords